Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence

BACKGROUND: Inevitably developed resistance of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) limited its clinical benefit on non-small cell lung cancer (NSCLC). Upfront combination therapy is promising to prevent this resistance. Compelling clinical ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ao, Luyao, Fang, Shencun, Zhang, Kexin, Gao, Yang, Cui, Jiawen, Jia, Wenjing, Shan, Yunlong, Zhang, Jingwei, Wang, Guangji, Liu, Jiali, Zhou, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063085/
https://www.ncbi.nlm.nih.gov/pubmed/35501907
http://dx.doi.org/10.1186/s13046-022-02369-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063085/
https://www.ncbi.nlm.nih.gov/pubmed/35501907
http://dx.doi.org/10.1186/s13046-022-02369-3

Ejemplares similares